Merrimack Pharmaceuticals Inc. (MACK) Announces Preliminary Data From Pilot Diagnostic Imaging Study Of MM-398
4/8/2014 7:32:41 AM
CAMBRIDGE, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol*, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment. Data from the first cohort of patients in this study were presented at the American Association of Cancer Research Annual Meeting, April 5-9, 2014, in San Diego, California.
Help employers find you! Check out all the jobs and post your resume.
comments powered by